Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Vahdat

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Nature Clinical Practice. Oncology|September 3, 2008
Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin?Linda Vahdat
The Oncologist|April 2, 2008
Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanismsLinda Vahdat
Clinical Breast Cancer|January 23, 2009
Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice settingTessa Cigler, Linda Vahdat
Anticancer Research|July 11, 2006
Dermatological toxicity of ixabepiloneAlison K Conlin, Linda Vahdat
Metal Ions in Life Sciences|March 12, 2019
Copper Depletion as a Therapeutic Strategy in CancerJay Lopez, Divya Ramchandani, Linda Vahdat
Breast Cancer Research and Treatment|May 16, 2019
Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysisJohn Silberholz, Dimitris Bertsimas, Linda Vahdat
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Measuring the impact of chemotherapy on fertility in women with breast cancerKutluk Oktay, Ozgur Oktem, Andrea Reh, et al.
Breast Cancer Research and Treatment|November 1, 2007
Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literatureKomal Jhaveri, Peter Halperin, Sandra J Shin, et al.
Melanoma Management|September 8, 2018
Copper suppression as cancer therapy: the rationale for copper chelating agents in <i>BRAF</i><sup>V600</sup> mutated melanomaSarah Sammons, Donita Brady, Linda Vahdat, et al.
Biomacromolecules|May 17, 2016
Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release PropertiesVanessa Bellat, Hyun Hee Lee, Linda Vahdat, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Nature Clinical Practice. Oncology|September 3, 2008
Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin?Linda Vahdat
The Oncologist|April 2, 2008
Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanismsLinda Vahdat
Clinical Breast Cancer|January 23, 2009
Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice settingTessa Cigler, Linda Vahdat
Anticancer Research|July 11, 2006
Dermatological toxicity of ixabepiloneAlison K Conlin, Linda Vahdat
Metal Ions in Life Sciences|March 12, 2019
Copper Depletion as a Therapeutic Strategy in CancerJay Lopez, Divya Ramchandani, Linda Vahdat
Breast Cancer Research and Treatment|May 16, 2019
Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysisJohn Silberholz, Dimitris Bertsimas, Linda Vahdat
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Measuring the impact of chemotherapy on fertility in women with breast cancerKutluk Oktay, Ozgur Oktem, Andrea Reh, et al.
Breast Cancer Research and Treatment|November 1, 2007
Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literatureKomal Jhaveri, Peter Halperin, Sandra J Shin, et al.
Melanoma Management|September 8, 2018
Copper suppression as cancer therapy: the rationale for copper chelating agents in <i>BRAF</i><sup>V600</sup> mutated melanomaSarah Sammons, Donita Brady, Linda Vahdat, et al.
Biomacromolecules|May 17, 2016
Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release PropertiesVanessa Bellat, Hyun Hee Lee, Linda Vahdat, et al.
Pageof 6